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Summary.-The effect of cyclophosphamide on MSV-H oncogenesis and the immune
response of young mice has been investigated. A single, sublethal dose (100 and
50 mg/kg of cyclophosphamide) in 8-day-old mice given 24 h before or after MSV-H
infection led to an earlier and lower incidence of tumours in comparison with con-
trols infected only with MSV-H.
The protective effect of cyclophosphamide, and the mechanism of action of both
cyclophosphamide and MSV-H on the target cells, mesenchymal cells in rapid
replication, as well the immunological implications of the findings are discussed.
CYCLOPHOSPHAMIDE (CY) is an alkyl-
ating agent with a potent cytostatic
and mitostatic activity on rapidly dividing
cells (van Putten and Lelieveld, 1970).
It prevents cell multiplication by cross-
linking strands of DNA, thus blocking its
replication (Brookes, 1964). CY is con-
verted in the liver into active compounds
(Foley, Freidman and Drolet, 1961]) which
are accumulated selectively in neoplastic
tissues (Brock and Hoorst, 1967). The
drug is widelyused as an antitumoural and
immunosuppressive agent. Several lines
of evidence indicate that immunology and
oncogenesis are potentially interactive
processes (Conference on Immunology of
Carcinogenesis, 1972). The effect of CY on
host immunity against tumours has been
investigated (Fefer, 1969; Bremberg, 1970;
Levij, Rwomusana and Polliack, 1970;
Moore and WVilliams, 1973).
A preferential effect of CY on the pool
of short-lived non-thymus-dependent B
lymphoctyes has been demonstrated by
Tuirk and Poulter (1972) and evidence of
niormal T-lymphocyte function associated
with reduced B-lymphocyte function
was given by Turk (1973), while Winkel-
stein (1973) pointed out the inhibitory
effect of CY on macrophages and their
precursors. Dumont (1974) demonstrated
in the mouse spleen after CY treatment
that T lymphocytes were also affected,
though to a much lesser extent than B
lymphocytes. Lagrange Makaness and
Miller (1974) showed in mice how treat-
ment with CY released T lymphocytes
from the inhibitory influence of the
humoral response, thus causing enhance-
ment of delayed-type hypersensitivity.
Murine sarcoma virus (Harvey) (MSV-H)
is an oncogenic virus affecting cells of
mesenchymal type and induces sarcoma-
tous tumours in mice and other rodents.
The effect ofMSV-H is strongly influenced
by the age of the host, being far more
effective in newborn than in older animals
(Harvey, 1964; Chesterman et al., 1966;
Harvey and East, 1971).
Fefer (1969) used CY on mice carrying
established murine sarcoma virus
(Moloney) (MSV-M)-induced tumours, and
reportedthatthetumours were moderately
sensitive to CY. However, the drug,
when given to young mice bearing primary
tumours transiently inhibited tumour
growth, whereas when given to normal
adult tumour-bearing mice, it decreased
tumour growth, but also depressed im-
munological reactivity, ultimately pre-
venting tumour regression. These
results demonstrated the risk of treatingM. BRANCA AND L. NICOLETTI
a host already positively reacting against
its own tumour with an antitumour drug
also possessing immunosuppressive
activity.
To define better some aspects of the
close relationship between the immune
capabilities of the host and tumour
susceptibility, we used an experimental
system in which young 8-9-days-old mice
have been treated with CY before and
after MSV-H infection.
The aims of the study were to examine
the effects of CY both on the immune
system in a host infected with an onco-
genic virus and on MSV-H oncogenesis.
MATERIALS AND METHODS
Mice.-Inbred BALB/c mice 8-9 days old
were obtained from the Animal Arsal
Laboratory, Pomezia, Rome.
Virus.-TheMSV-Hwasusedintheform of
tissue culture fluid (filtered through a 0-45 ,m
Millipore filter) from a virus-producer cell
line of BALB/c 3T3 transformed by MSV-H
(designated 3T3 + MSV-H and kindly pro-
vided by Dr Jennifer Harvey of the Clinical
Research Centre, Harrow, Middlesex, Eng-
land). 0-3 ml of a freshly filtered tissue
culture fluid was injected by s.c. into the
back.
Cyclophosphamide.-The cyclophospha-
mide (CY) was "Enoxana" (Asta Werke AG,
Brockwede, Germany) containing 0-9% NaCl
dissolved in distilled water immediately
before use. The drug was administered in a
single i.p. injection in doses of 150, 100 and
50 mg/kg body weight for each animal.
Schedule of treatment.-The experimental
groups (6 8-day-old mice per group) were
treated as follows:
(a) 3 groups inoculated i.p. with CY at
doses of 150, 100 or 50 mg/kg and then
24 h later with MSV-H s.c.
(b) 3 groups inoculated s.c. with 0 3 ml
MSV-H and then 24 h later with CY at
doses of 150, 100 or 50 mg/kg i.p.
(c) 3 groups inoculated with CY at doses of
150, 100 or 50 mg/kg i.p. only.
(d) 1 group inoculated s.c. with 0 3 ml
MSV-H only.
Mice of the same age inoculated with
saline solution were used as controls.
The animals were examined daily and then
killed at intervals of 2, 7, 10, 14, 21, 28 days
after the inoculation. In all the experiments
care was taken to have survivors in each
group.
Preparation of tissues for histology.-In-
guinal and axillary lymph nodes, spleen,
thymus,liver,lungandtumourswereremoved,
fixed on formal-acetic alcohol, sectioned at
5 ,um and stained with haematoxylin and
eosin.
RESULTS
Mice inoculatedfirst with CY and 24 h later
with MSV-H
In these groups the survival rate was
very low (Table I) and all the surviving
animals showed early signs of illness and
hair loss.
TABLE I.-Effect of CY on
Growth when Given Before
Infection of 8-day-old Mice
Inoculation with
Treatment MSV-H 24 h
with CY later Wit]
(mg/kg i.p.) (0 3 ml s.c.) Su
150 + 0/
100 + 2/
50 + 1/
150 0/-°
100 0/
50 - 0/l
+ 4/,
Tumour
MSV-H
h tumours
irvivors*
/2
/6 . 3/11
3 J
/3
/4 -0/13
6 J
/5
* Groups of 6 treated
At the pathological examination of
spleen and lymph nodes, already by the
2nd day after the CY inoculation at all
doses, marked hypoplasia ofthe lymphatic
structures was evident. The spleen and
lymph nodes showed marked reduction in
lymphocytes, particulary in the follicles,
germinal centres and cortico-medullary
junctions (non-thymus-dependent areas).
The lymphocytes round the central arter-
ioles of the spleen and the paracortical
areas of the lymph nodes (thymus-
dependent areas) were never completely
depleted in the same way (Figs. 1 and 2).
The areas of lymphocyte depletion were
evident in a background of reticulum
cells.
In the spleen, erythroblastosis in vari-
ous degrees was evident in all mice from
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FIG. 2-SiDleen 2 dsavs after treatment with
FIG. 1.-Spleen 2 days after treatment with 50 mg/kg of CY and then infection with
150 mg/kg of CY and then infection with MSV-H: marked depletion of lymphocytes
MSV-H: early lymphocytic depletion in in thenon-thymus-dependent areas. H. & E.
the non-thymus-dependent areas. H. & E. x 215
x 85.
the 7th day, as well as initial proliferation
of reticulum cells.
In these groups, tumours grew only in
mice treated with 100 and 50 mg/kg of
CY (Table I).
In all cases, spleen and lymph nodes
showed signs oflymphocyte repopulation,
beginning on Day 14, and remarkable
hyperplasia of reticular cells was also
evident at that time in the perifollicular
areas of lymphatic follicles (Fig. 3).
Only with the highest dose of CY
(150 mg/kg) was the thymus in two cases
noticeably hypoplastic with depletion of
lymphocytes in the cortex.
Mice inoculatedfirst with MSV-H and 24 h
later with CY
The survival rate was again low (Table
II) and the animals showed similar
symptoms of malaise. The spleen and the
lymph nodes exhibited a similar pattern
of lymphocytic depletion, mainly in the
non-thymus-dependent areas, beginning
2 days after the MSV-H inoculation (one
day after CY). Erythroblastosis of the
spleen was present at the 2nd day, but
only in the mice treated with 100 and 50
mg/kg of CY. Similar proliferation of
TABLE II.-EffectofCYon TumourGrowth
when given after MSV-H Infection of
8-day-old Mice
Inoculation Treatment with
with MSV-H CY 24 h later
(0-3 ml s.c.) (mg/kg i.p.)
+ 150
+ 100
+ 50
- 150
_ 100
- 50
±
* Groups of 6 treated
Mice with tumours
Survivors*
0/6
1/4 .2/15
1/5 J
0/3
0/4 .0/13
0/6 J
4/5 4/5
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FIG. 4.-Spleen 21 days after infection with
FIG. 3. Spleen 14 days after treatment with MSV-H before treatment with 50 mg of
CY (100 mg/kg) and then MSV-H: the CY: conspicuous diffuse proliferation of
lymphatic follicle shows signs of lympho- reticular cells. H. & E. x 215.
cytic repopulation and initial hyperplasia
ofret.iilar iells in the norifollicilair mranl+e
H. & E. x 215.
reticulum cells in the perifollicular areas
of splenic follicles as described in the CY
first group were also common becoming
noticeable on Day 21 (Fig. 4).
Tumour incidence was slightly lower in
this group (Table II). Only 2 tumours
were observed: a precocious peritoneal
tumour after 100 mg/kg of CY on Day 10
and an s.c. tumour after 50 mg/kg CY at
Day 21. Both tumours showed cystic
features and were sarcomatous in
appearance. Also in these groups, lympho-
cytic repopulation appeared at Day 14
(Fig. 5) then progressing very slowly.
Thymic hypoplasia was fairly common
and in a few cases "inversion" of thymic
pattern was observed (Fig. 6).
Mice inoculated with only CY
With all 3 doses ofCY, spleen andlymph
nodes were hypoplastic with lymphocytic
depletion mainly in the non-thymus-
dependent areas appearing 2 days after
drug inoculation and persisting until Day
14; signs of lymphocyte repopulation
were then evident, with complete re-
covery towards Day 28. Hypoplasia of
thymic cortex was often present.
Mice inoculated with MSV-H only
All mice presented early splenic ery-
throblastosis with haemorrhages and
tumour growth beginning on Day 21 at or
near the site ofvirus inoculation (Tables I
andII). Tumours (cystic andhaemorrhagic
sarcomas) progressed without signs of
regression.
DISCUSSION
A single, sublethal dose of CY (100 and
50 mg/kg) in 8-day-old mice, given 24 h
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FIm. 5. Spleen 14 days after infection with
MSV-H before treatment with 50 mg/kg
of CY: diffuse erythroblastosis and
proliferation of reticulum cells in the peri-
follicular areas and along the trabeculac.
H. & E. x 250.
before or after MSV-H infection, leads to
an earlier and lower incidence of tumours
thanin controlsinfectedonlywith MSV-H.
The incidence of tumours appears to be
closely related to the dose of CY (100 and
50 mg/kg) (Tables I and II). No tumours
were observed in either group treated
with 150 mg/kg of CY. The tumours also
appeared to be of a smaller size, whilst the
latest period was in 2 cases noticeably
shorter (10 days) in comparison with the
mean latent period of the control MSV-H-
infected mice (21 days).
Considering that CY is selectively
effective on cells in rapid replication we
can assume two mechanism of effect on
MSV-H oncogenesis. Firstly, CY can
directly destroy the mesenchymal cells,
the MSV-H target cells which are newly
transformed and dividing rapidly, espec-
ially if the drug is given after MSV-H
FIG. 6. Thymus of a mouse 14 days after
infection with MSV-H and then treatment
with 150 mg/kg of CY: marked cortical
lymphocytic depletion and inversion of
pattern. H. & E. x 85.
infection, thus displaying a direct selec-
tive mitostatic activity. In our experi-
ments, this argument is supported by the
fact that no tumours were observed in
mice treated with the highest dose of CY
(150 mg/kg), this presumably being
enough to destroy all MSV-H-transformed
cells.
A second mechanism of protection by
CY against MSV-H oncogenesis can be
assumed, considering the selective effect
of the drug on the immune system. The
results of the experiments show a protec-
tive activity by CY, even in a situation of
immunological deficiency due to the
youth of the animals and the immuno-
suppressive effect of the drug. In fact the
lymphatic organs showed a marked
preferential depletion in the non-thymus-
dependent areas
As is well known, CY selectively affects
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cells in rapid replication, such as the B
lymphocytes populating the non-thymus-
dependent areas, while less effective
against long-lived T lymphocytes. In this
way, cell-mediated immunity might not
be impaired completely and so remain
effective against the MSV-H infection and
transformation. As a hypothesis, it is
possible to think that the suppression of
B lymphocytes leads to the inhibition of
serum blocking antibodies produced by
the B lymphocytes, thus making the
transformed MSV-H tumour cells more
exposedtotheattackoftheTlymphocytes.
In conclusion, we consider the direct
cytostatic and mitostatic activity of CY
on the newly transformed cells to be of
primary importance and interest: in fact,
the mesenchymal cells, once transformed,
progress by rapid multiplication, so be-
coming target cells for the CY. This can
explain why CY given after MSV-H
prevents tumours.
Thus our results suggest that MSV-H
transforms rapidly dividing mesenchymal
cells, and that exposure to CY before or
soon after transformation can eliminate
these cells.
We are grateful for Dr A. C. Allison's
helpful advice. We thank Mr A. Morlino
for skilled technical assistance.
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